Menu

Pipeline Overview*

Pipeline Overview*

Drug** Indication Pre-clinical Phase 1/2 Phase 3 Marketed
Talicia®
(RHB-105)
H. pylori infection
Two positive US Phase 3 studies; NDA accepted for priority review
RHB-104 Crohn's disease
Positive top-line results from Phase 3 MAP US study
RHB-204 NTM infections
Pivotal Phase 3 study planned
Bekinda®
(RHB-102)
Gastroenteritis & gastritis
Positive results from Phase 3 U.S. study
IBS-D
Positive results from Phase 2 U.S. study
RHB-106 Bowel cleanser
WW rights licensed to Salix Pharmaceuticals
Yeliva® (ABC294640) Multiple indications
Cholangiocarcinoma and other indications
RHB-107 (MESUPRON) Oncology/GI
Completed multiple clinical studies
Other
RIZAPORT®
(RHB-103)
Migraine
U.S. NDA filed - re-submission of NDA planned following CRL
EUROPEAN MAA APPROVED UNDER THE EUROPEAN DECENTRALIZED PROCEDURE
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies ** Bekinda®, Yeliva® and Talicia® are proposed tradenames which are subject to FDA review and approval